Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - PROLOR Biotech, Inc. | v333893_ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - PROLOR Biotech, Inc. | v333893_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 6, 2013
PROLOR BIOTECH, INC.
(Exact Name of Registrant as Specified in Its Charter)
|
Nevada |
000-52691 |
20-0854033 |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
|
7 Golda
Meir Street |
| (Address of Principal Executive Office) |
Registrant’s telephone number, including area code (866) 644-7811
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD Disclosure.
On February 6, 2013, PROLOR Biotech, Inc., a Nevada corporation (the “Company”), issued a press release announcing that it will present preclinical data on its long-acting clotting Factor VIIa (Factor VIIa-CTP) at the Annual Congress of the European Association for Haemophilia and Allied Disorders (the “EAHAD Congress”), which is being held in Warsaw, Poland. The Company will present its data from 5:00-8:00 p.m. local time. A copy of the press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 7.01.
At the EAHAD Congress, the Company will additionally present a poster presentation, a copy which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference in this Item 7.01.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended.
ITEM 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
Description |
| 99.1 | Press Release, dated February 6, 2013 |
| 99.2 | Poster Presentation |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PROLOR BIOTECH, INC. | ||
| Date: February 6, 2013 | By: | /s/ Shai Novik |
| Shai Novik | ||
| President | ||
EXHIBIT INDEX
|
Exhibit Number |
Description |
| 99.1 | Press Release, dated February 6, 2013 |
| 99.2 | Poster Presentation |